abstract |
The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): Formula (I), R2 is selected from the group consisting of -C1-8alkyl-Z, -C2-8alkenyl-Z and -C2-8alkynyl-Z; wherein the -C1-8alkyl-Z, -C2-8alkenyl-Z and -C2-8alkynyl-Z and Z is a 5 to 6 member aromatic monocyclic heteroaryl ring having from 2 to 4 heteroatoms. These compounds are useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder. |